Omniflow II生物合成羊胶原移植物股腘位应用的当代结果
该多中心回顾性研究分析了2006至2014年间205例股腘位Omniflow II移植物旁路手术,术后5年膝上旁路一期通畅率71%、膝下40%,肢体挽救率分别为91%和87%。移植物生物降解(动脉瘤或狭窄)见于12.6%的移植物,需终身超声监测。
要点
- 膝上与膝下5年一期通畅率分别为71%和40%,肢体挽救率91%和87%
- 12.6%移植物发生动脉瘤样变或狭窄,16例需二次开放或腔内干预
- 建议终身双功超声监测,必要时二次干预
核心结论
- Omniflow II在股腘位提供满意的中长期通畅率和肢体挽救。
- 移植物可随时间发生动脉瘤样变或狭窄,需终身双功超声监测。
研究设计与样本
- 2006年1月至2014年1月两所三级中心连续205例股腘位Omniflow II旁路手术的回顾性分析。
- 194例患者、202条肢体,膝上54例、膝下151例。
主要发现
- 30天死亡率为3.9%,早期血栓性旁路闭塞占8.2%。
- 4例早期移植物感染经局部治疗成功保 graft。
- 平均(中位)随访56(55)个月(范围1-135个月)。
- 5年一期通畅率膝上71%、膝下40%,一期辅助通畅率78%和50%,二期通畅率78%和63%,肢体挽救率91%和87%。
- 移植物生物降解(动脉瘤或狭窄)26例(12.6%),16例接受二次开放或腔内手术。
临床怎么用
- 在缺乏自体静脉时,Omniflow II可用于股腘位旁路,尤其可能适用于污染野。
- 术后需终身双功超声监测移植物动脉瘤样变或狭窄,必要时二次干预。
局限性
- 回顾性分析设计。
- 仅两所三级中心经验,随访范围1-135个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to analyze the outcome of a contemporary series of femoropopliteal bypass operations with the glutaraldehyde denatured polyester mesh-reinforced ovine collagen prosthesis (OCP; Omniflow II [LeMaitre Vascular, Inc, Burlington, Mass]). The experience of two tertiary centers regarding long-term graft function, secondary reinterventions, and biodegeneration of the OCP prosthesis is presented. METHODS: Between January 2006 and January 2014, a series of 205 consecutive operations with the OCP in the femoropopliteal position (54 above knee and 151 below knee) were performed in 194 patients in 202 limbs for disabling claudication (72), chronic critical ischemia (105), acute ischemia (18), popliteal artery aneurysm (4), degeneration of a venous or prosthetic graft (5), and infection of a synthetic bypass graft (1). Grafts were observed with duplex ultrasound scan supplemented by additional angiography in case of recurrent ischemia with prospective documentation of follow-up data in a computerized vascular database. Retrospective analysis of graft patency, limb salvage, and diagnosis of aneurysmal graft degeneration was performed. RESULTS: The 30-day mortality was 3.9%. Early thrombotic bypass occlusion occurred in 8.2% of cases. Four early graft infections could be successfully managed by local treatment with graft preservation. After a mean (median) follow-up of 56 (55) months (range, 1-135 months), primary patency, primary assisted patency, secondary patency, and limb salvage were 71%, 78%, 78%, and 91% for above-knee bypass and 40%, 50%, 63%, and 87% for below-knee bypass at 5 years. Biodegeneration in the form of graft aneurysm or graft stenosis was detected in 26 grafts (12.6%), resulting in secondary open or endovascular procedures in 16 cases. CONCLUSIONS: The OCP provides satisfactory medium- and long-term patency and limb salvage in the femoropopliteal position. Aneurysmal degeneration or graft stenosis may develop over time, demanding lifelong duplex ultrasound surveillance and secondary intervention if needed. Its possible infection-resistant behavior in a contaminated field combined with an acceptable graft patency and limb salvage justifies the use of this graft in the absence of autologous vein.
引用
- Neufang A, Duenschede F, Espinola-Klein C, et al. Contemporary results with the biosynthetic glutaraldehyde denatured ovine collagen graft (Omniflow II) in femoropopliteal position. J Vasc Surg. 2019. PMID: 31870757. doi:10.1016/j.jvs.2019.08.234
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。